We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Dexcom Inc (DXCM) Common Stock USD0.001

Sell:$446.96 Buy:$447.37 Change: $8.44 (1.85%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $8.44 (1.85%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $8.44 (1.85%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Contact details

6340 Sequence Dr
United States
+1 (858) 2000200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$47.53 billion
Shares in issue:
96.92 million
Health Care Equipment
United States
US dollar

Key personnel

  • Kevin Sayer
    Chairman of the Board, President, Chief Executive Officer
  • Jereme Sylvain
    Chief Financial Officer, Executive Vice President
  • Sadie Stern
    Chief Human Resource Officer, Executive Vice President
  • Jacob Leach
    Executive Vice President, Chief Technology Officer
  • Donald Abbey
    Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs
  • Andrew Balo
    Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
  • Paul Flynn
    Executive Vice President - Global Revenue
  • Patrick Murphy
    Executive Vice President, Chief Legal Officer
  • Chad Patterson
    Executive Vice President - Global Marketing
  • Barry Regan
    Executive Vice President - Global Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.